Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
The goal of this single-arm study is to evaluate the efficacy and safety of Envafolimab
combined with Trifluridine/Tipiracil and Bevacizumab in the treatment of metastatic
colorectal cancer patients who are refractory or intolerant to standard therapy.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University